Glenmark Pharmaceuticals Ltd Share Price Today - Glenmark Pharmaceuticals Ltd Live Updates NSE/BSE

Glenmark Pharmaceuticals Ltd Share Price

NSEBSE

There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.

Max

Open2,242

High2,289.5

Low2,241.2

Prev. Close2,250.5

Avg. Traded Price2,264.33

Volume4,88,525

MARKET DEPTH

Total bid0.00

Total ask88.00

Orders	Qty	Bid
0	0	0
0	0	0
0	0	0
0	0	0
0	0	0

Ask	Qty	Orders
2250.5	2	88
0	0	0
0	0	0
0	0	0
0	0	0

HIGH/LOW

52w

LOW/HIGH

₹2241.2012 hours ago

₹2289.5012 hours ago

LOWER/UPPER CIRCUITS

₹2021.40

₹2470.60

Glenmark Pharmaceuticals Ltd Stock performance

KEY OBSERVATIONS

positive

negative

neutral

Annual Revenue,rose 29.83%, in the last year to ₹17,443.13 Cr. Its sector's average revenue growth for the last fiscal year was 12.19%.

Annual Net Profit,rose 30.06% in the last year to ₹1,361.85 Cr. Its sector's average net profit growth for the last fiscal year was 1.94%.

Price to Earning Ratio,is 35.26, lower than its sector PE ratio of 45.28.

LONG-TERM PRICE ANALYSIS

Stock return5Y CAGR : 8.17%

Net profit growth 5Y CAGR : %

STOCK RETURNS

Versus Nifty 50

1 w

-1.21%

-1.81%

1 mth

-3.74%

-3.27%

3 mth

-0.80%

-7.63%

6 mth

+4.10%

-6.2%

1 yr

+19.55%

-11.35%

3 yr

+185.96%

+13.23%

5 yr

+330.92%

+23.13%

Glenmark Pharmaceuticals Ltd Top mutual funds holding

HDFC Pharma and Healthcare Fund-Reg(G)

3Y Return+26.9%

NAV₹20.53

Bandhan Small Cap Fund-Reg(G)

3Y Return+21.2%

NAV₹51.19

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India, specialising in the research, development, manufacturing and sale of branded generics, generics, specialty medicines and OTC products across therapeutic areas including dermatology, respiratory, oncology, cardiology, diabetes, gynaecology, gastroenterology and anti‑infectives. The company operates in more than 80 countries, supported by 11 state‑of‑the‑art manufacturing sites and 4 R&D centres worldwide . Its shares are listed on the National Stock Exchange of India and BSE Limited.

Founded in 1977 by Mr. Gracias Saldanha, Glenmark’s journey features milestones such as: entry into dermatology with Candid Cream in 1979; the first manufacturing unit in Nashik in 1983; entry into respiratory care with Ascoril in 1987; the first R&D centre at Sinnar in 1999; establishing its North American subsidiary in 2003; European entry in 2004; and commissioning a US manufacturing facility at Monroe, North Carolina in 2014 . Recent strategic milestones include the creation of Ichnos Glenmark Innovation (IGI), out‑licensing agreements, and the completed divestment of a 75% stake in Glenmark Life Sciences to Nirma Limited.

Glenmark has sharpened its focus through “Glenmark 3.0” on its core therapy areas—Oncology, Dermatology and Respiratory—while continuing to build its pipeline via IGI and global in‑licensing partnerships . As of March 31, 2025, the Group comprised 43 subsidiaries, 37 of which were located outside India.

Glenmark Pharmaceuticals Limited Business Segments

Revenue by geography (FY 2025): India 33.7%; North America 22.6%; Europe 21.4%; Emerging Markets (Asia‑Pacific, Middle East & Africa, Russia & CIS, and Latin America) 21.1%.
Revenue by market: International markets contributed 66%, with India at 34%.

Glenmark Pharmaceuticals Limited Key Management

Glenn Saldanha – Chairman & Managing Director
Cherylann Pinto – Executive Director
S Mani – Executive Director & Global Chief Financial Officer
Harish Kuber – Company Secretary & Compliance Officer

Latest Updates on Glenmark Pharmaceuticals Limited

Oncology launches in India: TEVIMBRA (tislelizumab) for NSCLC and Brukinsa (zanubrutinib) for haematological malignancies.
Dermatology expansion: Winlevi (clascoterone cream 1%) received MHRA approval in the UK; launches across select European markets are planned for FY 2026.
Respiratory growth: Ryaltris was launched in more than 11 markets in FY 2025 and is now commercialised in 44 markets globally.
US generics momentum: 8 ANDA approvals and 13 product launches across oral solids, injectables, a semi‑solid ointment and an oral contraceptive in FY 2025.
Strategic partnerships: Collaborations included in‑licensing with global partners such as Pfizer (Abrocitinib; India brand name Jabryus), as well as arrangements related to Winlevi in Europe and South Africa.
Portfolio reshaping: Completed divestment of 75% stake in Glenmark Life Sciences to Nirma Limited.

Similar stocks

SUNPHARMA₹1764.00+17.60 (1.01%)

DIVISLAB₹9030.00+7.00 (0.08%)

TORNTPHARM₹4584.10+4.10 (0.09%)

ZYDUSLIFE₹1140.20+15.50 (1.38%)

LAURUSLABS₹2018.50-18.40 (0.90%)

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

What was Glenmark Pharmaceuticals Ltd's low today on the NSE?

The intraday low for Glenmark Pharmaceuticals Ltd on the NSE today was ₹2,241.20. The stock's 52-week low stands at ₹1,792.60, recorded on 28 Oct 2025. Today's low is 25.03% above the 52-week low, indicating the stock is trading well above its yearly lows.

What was today's high for Glenmark Pharmaceuticals Ltd share?

The intraday high for Glenmark Pharmaceuticals Ltd on the NSE today (15 Oct 2026) was ₹2,289.50. This compares to the 52-week high of ₹2,537.60 recorded on 28 Aug 2026. Today's high was -9.78% below the 52-week high.

How much return has Glenmark Pharmaceuticals Ltd given in the last 52 weeks?

Glenmark Pharmaceuticals Ltd has delivered 18.57% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹2,537.60 on 28 Aug 2026 and a 52-week low of ₹1,792.60 on 28 Oct 2025. It is currently trading at ₹2,250.50 as of 15 Oct 2026.

What is the highest Glenmark Pharmaceuticals Ltd share price ever recorded and when?

The all-time high (ATH) for Glenmark Pharmaceuticals Ltd was ₹2,515.00, recorded on 28 Aug 2026. At the current price of ₹2,250.50, the stock is trading 10.52% below its all-time high. The all-time low recorded was ₹188.10 on 23 Mar 2020.

What is the share price of Glenmark Pharmaceuticals Ltd?

As of 15 Oct 2026, the share price of Glenmark Pharmaceuticals Ltd is ₹2,250.50 on the NSE and ₹2,250.30 on the BSE. The stock opened at ₹2,242.00, touched a high of ₹2,289.50 and a low of ₹2,241.20 during today's session.

How much return has Glenmark Pharmaceuticals Ltd given in the last 6 months?

Over the last 6 months, Glenmark Pharmaceuticals Ltd has given a return of -0.55%. The stock was priced at ₹2,258.40 on 15 Apr 2026 and has Fallen to ₹2,250.50 as of 15 Oct 2026, a change of ₹7.90 per share.

What were the most recent reported sales and net income of Glenmark Pharmaceuticals Ltd?

For Q1 FY27, Glenmark Pharmaceuticals Ltd reported: Revenue (Net Sales): ₹24349.93 Cr - Up 13.44% year-on-year from ₹21465.76 Cr in Q4 FY26. Net Income (PAT): ₹7356.37 Cr - Up -1095.42% year-on-year from ₹-739.02 Cr in Q4 FY26.

What is the return of Glenmark Pharmaceuticals Ltd in the past 5 years?

Glenmark Pharmaceuticals Ltd has delivered a 332.76% absolute return over the past 5 years, equivalent to a CAGR of 34.04% per annum. The stock was priced at ₹520.03 in Oct 2021 and has risen to ₹2,250.50 as of 15 Oct 2026. An investment of ₹1,00,000 in Glenmark Pharmaceuticals Ltd five years ago would be worth ₹4,32,760.00 today.

Has Glenmark Pharmaceuticals Ltd offered any dividend in the past 5 years?

Yes,Glenmark Pharmaceuticals Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 15.00 per share between FY2022 and FY2026, with the most recent dividend of ₹2.50 per share for May 26, with an ex-dividend date of 31 Aug 2026. At the current market price of ₹2,250.50, the trailing dividend yield of Glenmark Pharmaceuticals Ltd stands at 7.50%.

How much return has Glenmark Pharmaceuticals Ltd given in the last 3 months?

Glenmark Pharmaceuticals Ltd has delivered a return of -2.24% over the last 3 months. The stock was trading at ₹2,297.40 on 15 Jul 2026 and is currently at ₹2,250.50 as of 15 Oct 2026, reflecting a Loss of ₹46.90 per share over this period.